摘要
目的:研究电针是否通过调节APP/PS1双转基因鼠低密度脂蛋白受体相关蛋白-1(LRP1)相关基因的表达,促进海马内Aβ淀粉样蛋白清除,探讨电针治疗阿尔兹海默病(AD)的机制。方法:6月龄APP/PS1双转基因小鼠24只,随机分为模型组、电针治疗组,以C57BL/6野生鼠12只作为正常对照组;采用Morris检测行为学,以激光共聚焦法观察皮层Aβ1-42及LRP1的共表达,免疫组化和RT-PCR法用来检测海马MEOX2、MYOCD、SREBP2表达。结果:Morris水迷宫检测显示,第2、4天,模型组与正常对照组比较,逃避潜伏时间增加(P<0.01),空间探索实验穿越平台次数、平台象限游泳路程显著减少(P<0.05,P<0.01);与模型组比较,电针治疗组逃避潜伏时间显著减少(P<0.05),穿越平台次数显著增加(P<0.05);RT-PCR结果显示,模型组MEOX2表达水平显著低于正常对照组(P<0.01),而电针治疗组高于模型组(P<0.01);模型组MYOCD、SREBP2的表达显著高于正常对照组(P<0.01),而电针治疗组低于模型组(P<0.01)。结论:电针治疗可改善APP/PS1双转基因小鼠学习记忆能力,可能跟上调MEOX2,降低MYOCD、SREBP2来干预Aβ转运受体LRP1相关。
Objective:To observe whether genes related to blood vessels of LRP1 can be adjusted by electro-acupuncture(EA)to strength the clearance of Aβin hippocampus of APP/PS1 transgenic mice,and to explore the mechanism of the EA therapy for Alzheimer’s disease(AD).Methods:Twenty-four 6-month-old APP/PS1 transgenic mice were randomly divided into model group and EA group,with twelve C57 BL/6 wild type mice as the normal control group.The Morris water maze was used to assess learning-memorize ability.Laser scanning confocal microscope was adopted to observe the expression of LRP1 and Aβ1-42 in hippocampus.MEOX2,MYOCD and SREBP2 were detected by immunohistochemistry and RT-PCR method.Results:The Morris water maze test showed the escape latency of model group increased(P<0.01),and the number of platform-site crossover and the swimming distance in platform quadrant of model group were reduced compared with the normal group(P<0.05,P<0.01),while the EA group could revise them(P<0.05).The RT-PCR results showed that the level of MEOX2 in the model group was lower than that in the normal group(P<0.01),while the EA group could raise its expression(P<0.01).The expression of MYOCD and SREBP2 in the model group was higher than that in the normal group(P<0.01),while the EA group was lower than the model group(P<0.01).Conclusion:EA therapy can improve the learning-memorize ability of the APP/PS1 transgenic mice.The mechanism may be related to the up-regulation of MEOX2 and decrease of MYOCD and SREBP2 in hippocampus to interfere with Aβtransport receptor LRP1.
作者
王鑫
许安萍
孙敬青
薛卫国
WANG Xin;XU An-ping;SUN Jing-qing;XUE Wei-guo(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2019年第12期5849-5853,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.81273826,No.81603680)
针灸神经调控北京市重点实验室(No.BZ0437).
